<DOC>
	<DOCNO>NCT01202812</DOCNO>
	<brief_summary>The purpose study determine effectiveness LOVAZA ( fish oil capsule ) decrease inflammation child adolescent Sickle Cell Disease ( SCD ) . It find besides damage cause sickle red blood cell , inflammatory response occur SCD patient could potentially play significant role occurrence painful episode pain crisis . The investigator also study whether subject/caregiver feel improvement child 's quality life take medication . Besides effect LOVAZA inflammation , investigator also test whether drug beneficial effect blood clot ability ( know increase SCD ) anemia ( low red blood cell ) part disease entity .</brief_summary>
	<brief_title>A Randomized Trial LOVAZA Pediatric Sickle Cell Disease ( SCD )</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<criteria>Subjects meet follow criterion eligible enrollment study : Participant sign inform consent/assent parent signing inform consent age appropriate . Established diagnosis HbSS HbSβo Thal . History ≥3 vasocclusive pain event precede 12 month . Regular compliance comprehensive care . Aged 10 year great less 20 year . At enrollment , subject his/her steady baseline state . Exclusion Criteria Subjects Hb level &lt; 5.5gm/dL . Inability take tolerate oral medication . Poor compliance previous treatment regimen . Hepatic dysfunction ( SGPT also know ALT &gt; 2X upper limit normal conjugate bilirubin &gt; 2X patient baseline within last 6 week ) . Renal dysfunction ( A creatinine level within past 6 week ≥ 1.0mg/dL child ≥ 1.2mg/dL subject ≥ 18 year age ) . Allergy fish shell fish . Triglyceride level &lt; 80mg/dL . Pregnancy . Chronic Transfusion Therapy . Transfusion within last 30 day . Persistent pain sicklecomplications ( e.g . avascular necrosis ) . A vasocclusive pain episode lasting longer 2 week &gt; 12 pain episode precede year . Daily narcotic usage . Treatment investigational drug regular fish oil supplementation last 60 day . Currently receive another investigational agent , agent last 60 day . Dosage change precede 3 month hydroxyurea . Bleeding disorder patient concomitant anticoagulation . Conditional abnormal TCD result stroke . Other chronic illness could adversely affect subject performance HIV TB . Children Care ( CiC ) : A child care child place control protection agency , organization , institution entity court , government government body , act accordance power confer law regulation .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Sickle Cell Anemia</keyword>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Hemoglobin SS Disease</keyword>
	<keyword>Hemoglobin S beta-0 Thalassemia</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Sickle Thalassemia</keyword>
	<keyword>C-Reative Protein</keyword>
	<keyword>Hemolytic Anemia</keyword>
	<keyword>Hemostasis</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Coagulation</keyword>
	<keyword>Omega-3 Fatty Acids</keyword>
	<keyword>Eicosapentaenoic Acid</keyword>
	<keyword>Docosahexaenoic Acid</keyword>
	<keyword>Fish Oils</keyword>
	<keyword>Drug : Placebo</keyword>
	<keyword>Drug : LOVAZA</keyword>
</DOC>